How AstraZeneca Reduced Zero-Enrolling Sites and Drove More Predictable Enrollment Through Real-World Site Intelligence

Session details:

AstraZeneca presents how their Site Engagement Team integrated real-world site intelligence, honest capacity conversations, and proactive partnership strategies into feasibility and site selection—resulting in fewer zero-enrolling sites, accelerated first site initiation (FSI), stronger enrollment performance, and more accurate feasibility projections across studies. Key topics include:

• How trust-based sponsor-site relationships enabled more transparent conversations around bandwidth, staffing, competing trials, and operational readiness
• How real-world site intelligence informed feasibility and country/site selection to improve enrollment predictability and increase the proportion of target-hitting sites
• Real-world outcomes and lessons learned from structured feedback loops, proactive engagement models, and cross-functional collaboration across therapeutic areas